GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gossamer Bio Inc (NAS:GOSS) » Definitions » Change In Payables And Accrued Expense

GOSS (Gossamer Bio) Change In Payables And Accrued Expense : $5.5 Mil (TTM As of Mar. 2025)


View and export this data going back to 2019. Start your Free Trial

What is Gossamer Bio Change In Payables And Accrued Expense?

Gossamer Bio's Change In Payables And Accrued Expense for the quarter that ended in Mar. 2025 was $0.5 Mil. It means Gossamer Bio's Accounts Payable & Accrued Expense increased by $0.5 Mil from Dec. 2024 to Mar. 2025 .

Gossamer Bio's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2024 was $-8.1 Mil. It means Gossamer Bio's Accounts Payable & Accrued Expense declined by $8.1 Mil from Dec. 2023 to Dec. 2024 .

Gossamer Bio Change In Payables And Accrued Expense Historical Data

The historical data trend for Gossamer Bio's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gossamer Bio Change In Payables And Accrued Expense Chart

Gossamer Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Change In Payables And Accrued Expense
Get a 7-Day Free Trial Premium Member Only 0.87 1.78 -2.43 -8.03 -8.13

Gossamer Bio Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Change In Payables And Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -13.16 2.90 0.31 1.81 0.51

Gossamer Bio Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $5.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gossamer Bio Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Gossamer Bio's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Gossamer Bio Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gossamer Bio Inc (NAS:GOSS) » Definitions » Change In Payables And Accrued Expense
Comparable Companies
TVRD CADL OCGN CRVS TSVT ALMS PHAT TERN HRTX PVLA VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
4GB:Germany
Address
3115 Merryfield Row, Suite 120, San Diego, CA, USA, 92121
Website
https://www.gossamerbio.com
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
Executives
Richard Aranda officer: Chief Medical Officer 3013 SCIENCE PARK ROAD, SAN DIEGO CA 92121
Faheem Hasnain director, officer: Executive Chairman 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
Bryan Giraudo officer: Chief Financial Officer 7707 GATEWAY BOULEVARD, SUITE 140, NEWARK CA 94560
Waage Christian officer: EVP & General Counsel RECEPTOS, INC., 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121
Caryn Peterson officer: EVP, Regulatory Affairs 3013 SCIENCE PARK ROAD, SAN DIEGO CA 92121
Sandra Milligan director 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Laura Carter officer: Chief Scientific Officer 3013 SCIENCE PARK ROAD, SAN DIEGO CA 92121
Luisa Salter-cid officer: Chief Scientific Officer C/O GOSSAMER BIO, INC., 3013 SCIENCE PARK ROAD, SUITE 200, SAN DIEGO CA 92121
Jakob Dupont officer: Chief Medical Officer C/O ONCOMED PHARMACEUTICALS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Sheila Gujrathi director, officer: President & CEO 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121
Omega Fund V Gp, L.p. 10 percent owner 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Omega Fund V Gp Manager, Ltd. 10 percent owner 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Omega Fund V, L.p. 10 percent owner 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Otello Stampacchia director, 10 percent owner 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Russell J. Cox director C/O JAZZ PHARMACEUTICALS, PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2